Jovanovic Hristina, Karlsson Per, Cerin Asta, Halldin Christer, Nordström Anna-Lena
Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Stockholm, Sweden.
Psychiatry Res. 2009 Apr 30;172(1):31-7. doi: 10.1016/j.pscychresns.2008.07.002. Epub 2009 Jan 1.
The aim of the present study was to explore the effects of the menstrual cycle phases on 5-HT(1A) receptor and 5-HTT binding potentials (BPs) in healthy women by using positron emission tomography (PET). Women were investigated in the follicular and luteal phase of the menstrual cycle with radioligands [(11)C]WAY10035 (n=13) and [(11)C]MADAM (n=8) to study 5-HT(1A) and 5-HTT BPs. The BPs values were quantified using the simplified reference tissue model. The phases of the menstrual cycle were characterized by transvaginal ultrasound (TSV) and plasma levels of hormones estradiol (E(2)), progesterone (P(4)), follicle stimulating hormone (FSH) and luteinizing hormone (LH).The 5-HT(1A) receptor and 5-HTT BPs did not significantly differ between follicular and luteal phases in any of the investigated regions. There were no significant correlations between the change in E(2) or P(4) values with the change in 5-HT(1A) receptor or 5-HTT BPs. The results provide principally a new in vivo finding in human female biology, suggesting the absence of influence of menstrual cycle phase on 5-HT(1A) receptors or 5-HTT. The finding however does not preclude that gonadal hormones differentially influence central serotonin system inwomen and men, which might contribute to gender differences in serotonin-associated disorders.
本研究的目的是通过正电子发射断层扫描（PET）探索月经周期各阶段对健康女性5-羟色胺（5-HT）1A受体和5-羟色胺转运体（5-HTT）结合潜能（BP）的影响。在月经周期的卵泡期和黄体期，使用放射性配体[（11）C]WAY10035（n = 13）和[（11）C]MADAM（n = 8）对女性进行研究，以探讨5-HT1A和5-HTT的BP。使用简化参考组织模型对BP值进行定量。月经周期各阶段通过经阴道超声（TSV）以及激素雌二醇（E（2））、孕酮（P（4））、卵泡刺激素（FSH）和黄体生成素（LH）的血浆水平来表征。在任何研究区域，卵泡期和黄体期之间的5-HT1A受体和5-HTT BP均无显著差异。E（2）或P（4）值的变化与5-HT1A受体或5-HTT BP的变化之间无显著相关性。这些结果主要提供了人类女性生物学中的一项新的体内研究发现，表明月经周期阶段对5-HT1A受体或5-HTT没有影响。然而，这一发现并不排除性腺激素对女性和男性中枢5-羟色胺系统有不同影响，这可能导致5-羟色胺相关疾病的性别差异。
